Toward new therapeutics for skin and soft tissue infections: Propargyl-Linked antifolates are potent inhibitors of MRSA and streptococcus pyogenes

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Viswanathan, Kishore ^a   Frey, Kathleen M ^a   Scocchera, Eric W ^a   Martin, Brooke D ^b   Swain III, P Whitney ^b   Alverson, Jeremy B ^b   Priestley, Nigel D ^b   Anderson, Amy C ^a   Wright, Dennis L ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Promiliad Biopharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; METICILLIN; VANCOMYCIN; ALKYNE; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; MAMMAL CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PROCESS OPTIMIZATION; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PYOGENES; STRUCTURE ANALYSIS; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; SKIN DISEASE; SPECIES DIFFERENCE;

MAMMALIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

ALKYNES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FOLIC ACID ANTAGONISTS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; SKIN DISEASES; SOFT TISSUE INFECTIONS; SPECIES SPECIFICITY; STREPTOCOCCUS PYOGENES; VANCOMYCIN;

EID: 84856755045     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029434     Document Type: Article

References (34)

1. NNIS (2004) National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32: 470-485.
2. Proctor R, (2008) Role of Folate Antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 46: 584-593.
3. Kluytmans-VandenBergh M, Kluytmans J, (2006) Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin Microbiol Infect 12 (suppl. 1): 9-15.
4. Kollof M, Micek S, (2006) Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen? Curr Opin Infect Dis 19: 161-168.
5. Appelbaum P, (2006) MRSA- the tip of the iceberg. Clin Microbiol Infect 12 (Suppl. 2): 3-10.
6. Drew R, (2007) Emerging Options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 27: 227-249.
7. Huovinen P, Sundstrom L, Swedberg G, Skold O, (1995) Trimethoprim and Sulfonamide Resistance. Antimicrob Agents and Chem 39: 279-289.
8. Hawser S, Luciuro S, Islam K, (2006) Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 71: 941-948.
9. Schneider P, Hawser S, Islam K, (2003) Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 13: 4217-4221.
10. Sincak C, Schmidt J, (2009) Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections. Ann Pharmacother 43: 1107-1114.
11. Evolva, (2009) FDA issues complete response letter for iclaprim. Available: http://www.evolva.com/press-investors/newsroom/press-releases/2009/1/19/fda-issues-complete-response-letter-iclaprim. Accessed 2011 Sept 20.
12. Darmstadt G, (1997) Oral antibiotic therapy for uncomplicated bacterial skin infections in children. Pediatr Infect Dis J 16: 227-240.
13. Stevens D, Bisno A, Chambers H, Everett E, Dellinger P, et al. (2005) Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41: 1373-1406.
14. Schito G, (2006) The importance of the development of antibiotic resistance in Staphylococcus aureus. Clin Microbiol Infect 12: 3-8.
15. Nichols R, (1999) Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 44: 19-23.
16. Richter S, Heilmann K, Dohrn C, Beekman S, Riahi F, et al. (2008) Increasing telithromycin resistance among Streptococcus pyogenes in Europe. J Antimicrob Chemother 61: 603-611.
17. Amyes S, (1982) Bactericidal Activity of Trimethoprim Alone and in Combination with Sulfamethoxazole on Susceptible and Resistant Escherichia coli K-12. Antimicrob Agents and Chem 21: 288-293.
18. Then R, Angehrn P, (1973) Nature of the Bactericidal Action of Sulfonamides and Trimethoprim, Alone and in Combination. J Inf Dis 128: S498-S501.
19. Frey K, Liu J, Lombardo M, Bolstad D, Wright D, et al. (2009) Crystal Structures of Wild-type and Mutant Methicillin-resistant Staphylococcus aureus Dihydrofolate Reductase Reveal an Alternative Conformation of NADPH that may be Linked to Trimethoprim Resistance. J Mol Biol 387: 1298-1308.
20. Frey K, Georgiev I, Donald B, Anderson A, (2010) Predicting resistance mutations using protein design algorithms. Proc Natl Acad Sci 107: 13707-13712.
21. Frey K, Lombardo M, Wright D, Anderson A, (2010) Towards the Understanding of Resistance Mechanisms in Clinically Isolated Trimethoprim-resistant, Methicillin-resistant Staphylococcus aureus Dihydrofolate Reductase. J Struc Biol 170: 93-97.
22. Bolstad D, Bolstad E, Frey K, Wright D, Anderson A, (2008) A structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from Cryptosporidium. J Med Chem 51: 6839-6852.
23. Pelphrey P, Popov V, Joska T, Beierlein J, Bolstad E, et al. (2007) Highly efficient ligands for DHFR from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis. J Med Chem 50: 940-950.
24. Kerns E, Di L, (2008) Drug-like Properties: Concepts, Structure Design and Methods Burlington, MA Academic Press.
25. Vickers A, Potter N, Fishwick C, Chopra I, O'Neill A, (2009) Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques. J Antimicrob Chemother 63: 1112-1117.
26. O'Neill A, Chopra I, (2004) Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin Investig Drugs 13: 1045-1063.
27. Then R, Kohl I, Burdeska A, (1992) Frequency and transferability of trimethoprim and sulfonamide resistance in methicillin-resistant Staphylococcus aureus and Staphylococcus epidermis. J Chemother 4: 67-71.
28. Nadanaciva S, Lu S, Gebhard D, Jessen B, Pennie W, et al. (2011) A high content screening assay for identifying lysosomotropic compounds. Toxicol in vitro 25: 715-723.
29. Ndolo R, Forrest ML, Krise J, (2010) The role of lysosomes in limiting drug toxicity in mice. J Pharmacol Exp Ther 333: 120-128.
30. Jansen G, Barr H, Kathmann I, Bunni M, Priest D, et al. (1999) Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools and intralysosomal drug sequestration. Mol Pharmacol 55: 761-769.
31. Marshall L, Rhee M, Hofmann L, Khodjakov A, Schneider E, (2005) Increased lysosomal uptake of methotrexate-polyglutamates in two methotrexate-resistant cell lines with distinct mechanisms of resistance. Biochem Pharmacol 71: 203-213.
32. McCoy A, (2007) Solving structures of protein complexes by molecular replacement with Phaser. Acta Cryst D63: 32-41.
33. Wiegand I, Hilpert K, Hancock R, (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3: 163-175.
34. Lorian V, (2005) Antibiotics in Laboratory Medicine Philadelphia Lippincott, Williams and Wilkins.